There’s nothing hotter than idarucizumab, the reversal agent for dabigatran. It’s so hot, the New England Journal of Medicine once published a farcical 91 patient interim analysis of a planned 500 patient enrollment. Now, two years later, we have the full cohort and it’s, well, more of the same, with all the flaws previewed in … Continue reading Idarucizumab, the Sequel